Ocugen CEO Musunuri Shankar sold 525,991 shares at $1.12 per share through two transactions on 2026-09-09. The report matters to investors because it records the CEO’s post-sale ownership at 1,088,035 shares, identifying the stake remaining after the disclosed transactions.
Key Highlights
- The transactions were completed on 9 September 2026.
- Both transactions were reported under code S.
- Musunuri Shankar owned 1,088,035 shares after the transactions.
Ocugen, Inc. (NASDAQ: OCGN) CEO Musunuri Shankar sold 525,991 shares at $1.12 per share across two transactions. The sales were completed on 9 September 2026.
at $1.12 The transactions were reported under SEC transaction code S. Shankar serves as Ocugen’s chief executive officer. Each transaction was priced at $1.12 per share, bringing the combined number of shares sold to 525,991. The filing reports the sales and Shankar’s subsequent Ocugen share ownership. at 1,088,035 Shares Shankar owned 1,088,035 shares after completing the two transactions. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many Ocugen shares did CEO Musunuri Shankar sell?
A: Ocugen CEO Musunuri Shankar sold 525,991 shares across two transactions. Both sales were priced at $1.12 per share and took place on 9 September 2026.
Q: What was the reported impact of the Ocugen CEO stock sale?
A: The filing reports 525,991 shares sold and 1,088,035 shares owned afterward. It provides the post-transaction ownership figure but does not describe any other impact.
Q: What transaction code was used for the Ocugen insider sale?
A: The filing reports both Ocugen transactions under code S. Together, they involved 525,991 shares, with the transactions reported at $1.12 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.